enGene (ENGN) Stock Price, News & Analysis

Company Overview

enGene is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

Key Stats

• Today's Range: $1.70 to $2.24
• 50-Day Range: $1.72 to $10.11
• 52-Week Range: $1.70 to $12.25
• Volume: 23.89 million shs
• Average Volume: 406,007 shs
• Market Capitalization: $115.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.69
• Consensus Rating: Moderate Buy

enGene Stock Analysis - MarketRank™

enGene scored higher than 67% of companies evaluated by MarketBeat, and ranked 227th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

enGene has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 7 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

enGene has a consensus price target of $22.69, representing about 1,219.0% upside from its current price of $1.72.

Amount of Analyst Coverage

enGene has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for enGene are expected to grow in the coming year, from ($2.06) to ($1.90) per share.

Price to Book Value per Share Ratio

enGene has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.22% of the float of enGene has been sold short.

Short Interest Ratio / Days to Cover

enGene has a short interest ratio ("days to cover") of 6.67.

Change versus previous month

Short interest in enGene has recently increased by 16.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

enGene does not currently pay a dividend.

Dividend Growth

enGene does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.41

News Sentiment

enGene has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for enGene this week, compared to 10 articles on an average week.

Search Interest

2 people have searched for ENGN on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, enGene insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENGN Stock Analysis - Frequently Asked Questions

How have ENGN shares performed this year?

enGene's stock was trading at $9.03 at the beginning of the year. Since then, ENGN shares have decreased by 81.0% and is now trading at $1.72.

How were enGene's earnings last quarter?

enGene Holdings Inc. (NASDAQ:ENGN) released its quarterly earnings results on Monday, March, 9th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.11.

Who are enGene's major shareholders?

enGene's top institutional shareholders include Dimensional Fund Advisors LP (0.06%). Insiders that own company stock include De Solidarite Des Travai Fonds, Growth Opportunities F Forbion and Ronald Harold Wilfred Cooper.
View institutional ownership trends.

How do I buy shares of enGene?

Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of enGene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that enGene investors own include PayPal (PYPL), United Microelectronics (UMC), XPENG (XPEV), Adverum Biotechnologies (ADVM), AngioDynamics (ANGO), APi Group (APG) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 3/09/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 6/11/2026
• Fiscal Year End: 10/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENGN
• Previous Symbol: NASDAQ:ENGN
• CIK: 1980845
• Web: www.engene.com
• Phone: 302-273-0765
• Fax: N/A
• Employees: 31
• Year Founded: 1999

Price Target and Rating

• Average Price Target for enGene: $22.69
• High Price Target: $30.00
• Low Price Target: $10.00
• Potential Upside/Downside: +1,219.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$117.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -55.83%
• Return on Assets: -45.74%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 11.75
• Quick Ratio: 11.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.60 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 66,990,000
• Free Float: 60,019,000
• Market Cap: $115.22 million
• Optionable: N/A
• Beta: -0.02